A Phase I, Multi-Center, Dose-Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of AV-412 Administered Orally Three Times Weekly to Subjects With Advanced Solid Tumors

The Epidermal Growth Factor Receptor (EGFR) is a validated target for the treatment of cancer, and agents targeting EGFR such as erlotinib (Tarceva®) are approved by the FDA for treatment of various solid tumors. AV-412 is a novel inhibitor of the EGFR-tyrosine kinase, with added activity against Her2 and other oncogenic kinases. Based on evidence of preclinical activity in various solid tumors, AV-412 is being developed as a possible novel treatment for cancer in humans.
PURPOSE: The purpose of this study is to test the safety and tolerability of AV-412, and determine the maximum tolerated dose of AV-412 when administered orally three times weekly.

开始日期2007-10-01

申办/合作机构

AVEO Pharmaceuticals, Inc.

NCT00381654 / Terminated临床1期

A Phase 1, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients With Refractory or Relapsed Solid Tumor Malignancies

AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who have not responded to standard therapy or surgical interventions, or who have experienced relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose for the treatment of solid tumors.

开始日期2006-10-01

申办/合作机构

AVEO Pharmaceuticals, Inc.

100 项与 MP-412 相关的临床结果

登录后查看更多信息

100 项与 MP-412 相关的转化医学

登录后查看更多信息

100 项与 MP-412 相关的专利（医药）

登录后查看更多信息

项与 MP-412 相关的文献（医药）

2010-01-01·IDrugs : the investigational drugs journal

AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 2.

Article

作者: Walker, Karen ; Padhiar, Meenal

The 21st international symposium of the American Association for Cancer Research (AACR), the NCI and the European Organization for Research and Treatment of Cancer (EORTC), held in Boston, included topics covering the development of therapeutics and molecular targets in the field of cancer research. This conference report highlights selected presentations on the development of novel drugs for cancer. Investigational drugs discussed include RO-506876 (F Hoffmann-La Roche Ltd), GDC-0980 (Genentech Inc), EMD-1214063 and EMD-1204831 (Merck Serono SA), AR-mTOR01 and AR-mTOR-26 (Array BioPharma Inc), GSK-2126458 (GlaxoSmithKline plc), EXEL-1415 and EXEL-2008 (Exelixis Inc), FP-1039 (FivePrime Therapeutics Inc), and AV-412 (AVEO Pharmaceuticals Inc).

100 项与 MP-412 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	MP-412	-	DB06021

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期癌症	临床2期	美国	AVEO Pharmaceuticals, Inc.	2007-10-01
晚期恶性实体瘤	临床2期	美国	AVEO Pharmaceuticals, Inc.	2007-10-01
难治性癌症	临床2期	美国	AVEO Pharmaceuticals, Inc.	2007-10-01
难治恶性实体肿瘤	临床2期	阿根廷	AVEO Pharmaceuticals, Inc.	2006-10-01
难治恶性实体肿瘤	临床2期	美国	AVEO Pharmaceuticals, Inc.	2006-10-01
肿瘤	临床2期	-	Mitsubishi Tanabe Pharma Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2010	临床1期	HR阳性/HER2低表达实体瘤	36	AV-412	(衊壓選齋壓窪齋簾鬱築) = 齋襯齋醖積壓網觸積鹹餘構膚艱獵餘簾築積遞 (膚鹽蓋壓糧顧憲積鏇鹽 ) 更多	-	2010-05-20